Amendments for: 172-2021-2022-Q2-974365
Current (Sep 29, 2021)
Agreement: Preclinical Efficacy of Gene Therapy in Brain and Ocular Applications (974365). May 1, 2021 - Mar 18, 2022
Description:
The proposed project will involve repeat dose testing in a Huntington's Disease model to demonstrate the ability to perform titratable genome editing. Additionally the project will involve proof of concept testing in other organ models of genetic disease.
Expected Results:The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Organization: National Research Council CanadaRecipient: Incisive Genetics Inc. (For-profit organization)
Location: Vancouver, British Columbia, CA V6S 1Z3
Type: Contribution
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 252,000 dollars.
Federal Riding Name: Vancouver Quadra (59039)Program Name: Industrial Research Assistance Program – Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.NAICS Code: 541710